Eva Steiness
Vorsitzender bei Phlogo ApS
Ursprung des Netzwerks ersten Grades von Eva Steiness
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 45 | |
10
| Private Company | Biotechnology | 10 |
| Public Company | Pharmaceuticals: Major | 10 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Eva Steiness
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| University of Copenhagen | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree Doctorate Degree Corporate Officer/Principal Undergraduate Degree Corporate Officer/Principal Doctorate Degree Graduate Degree Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| University of Aarhus | College/University | Corporate Officer/Principal Graduate Degree Graduate Degree Masters Business Admin Graduate Degree Undergraduate Degree | |
| Copenhagen Business School | College/University | Undergraduate Degree Graduate Degree Graduate Degree Masters Business Admin Graduate Degree Graduate Degree | |
| University of Lund | College/University | Graduate Degree Doctorate Degree Graduate Degree Undergraduate Degree | |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer Chairman Director/Board Member Founder | |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member Chairman | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member Director/Board Member | |
| ATON | Pharmaceuticals: Major | Director/Board Member Chairman Chairman | |
| Technical University of Denmark | College/University | Graduate Degree Graduate Degree Undergraduate Degree | |
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Financial Conglomerates | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Director/Board Member | |
| University of Oxford | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Norwegian School of Economics & Business Administration | College/University | Masters Business Admin Graduate Degree Graduate Degree | |
| International Institute for Management Development | College/University | Masters Business Admin Undergraduate Degree Masters Business Admin | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| VALNEVA | Biotechnology | Corporate Officer/Principal Director/Board Member | |
| NEL ASA | Industrial Machinery | Director/Board Member Chairman | |
| University of Uppsala | College/University | Corporate Officer/Principal Doctorate Degree | |
| NUPATHE INC | Medical Specialties | Founder Corporate Officer/Principal | |
Dako Denmark ApS
 Dako Denmark ApS Medical SpecialtiesHealth Technology Dako Denmark A/S designs and manufactures cancer diagnostic systems. It produces reagents, antibodies, instruments, and software solutions to make diagnoses and determine treatments for patients suffering from cancer. The firm's product areas encompass Immunohistochemistry, pharmacoDiagnostics, molecular pathology, Hematoxylin and Eosin stain, special stains, flow Cytometry, and specific proteins. The company was founded by Niels Harboe in 1966 and is headquartered in Glostrup, Denmark. | Medical Specialties | Director/Board Member Chief Executive Officer | |
| Danmarks Farmaceutiske Universitet | College/University | Graduate Degree Graduate Degree | |
| AVT Business School A/S | College/University | Chairman Masters Business Admin | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
| NTG NORDIC TRANSPORT GROUP A/S | Trucking | Corporate Officer/Principal Investor Relations Contact | |
| SILENCE THERAPEUTICS PLC | Miscellaneous Commercial Services | Chief Executive Officer Chief Operating Officer | |
| EGETIS THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member Chairman | |
EffRx Pharmaceuticals SA
 EffRx Pharmaceuticals SA Pharmaceuticals: OtherHealth Technology EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland. | Pharmaceuticals: Other | Director/Board Member Chief Operating Officer | |
Step Pharma SAS
 Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Pharmaceuticals: Major | Chairman Chief Executive Officer | |
Royal Swedish Academy of Engineering Sciences
 Royal Swedish Academy of Engineering Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Engineering Sciences (IVA) is an organization that brings together around 1,300 academy members and 250 companies to bridge the gap between academia, business, and politics. The non-profit company is based in Stockholm, Sweden. The Swedish company's aim is to work towards people's ability to contribute positively to society. The organization runs an internship program called Tekniksprånget, which gives young people in Sweden the opportunity to test the engineering profession through a four-month paid internship. The program has been running since 2012 and aims to inspire more people to choose a higher technical education. The CEO of the company is Björn O. Nilsson. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
Pharma Guidance ApS
 Pharma Guidance ApS Miscellaneous Commercial ServicesCommercial Services Pharma Guidance ApS supports small and medium-sized companies in the drug development process. The private company is based in Vedbaek, Denmark. The Danish company was founded by Torben Skarsfeldt, who has been the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer | |
| University of Southern Denmark | College/University | Corporate Officer/Principal Masters Business Admin | |
Kymab Group Ltd.
 Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Key Neurosciences SAS
 Key Neurosciences SAS Miscellaneous Commercial ServicesCommercial Services Key Neurosciences SAS provides research and development services. Its services include product and technology development, fund raising, business and commercial development, and project management. The company was founded in December 2010 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
| ADOCIA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| VELOXIS PHARMACEUTICALS A/S | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
| BAVARIAN NORDIC A/S | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Zymenex A/S
 Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Biotechnology | Chairman Chairman | |
| CELLECTIS S.A. | Pharmaceuticals: Major | Director/Board Member Director/Board Member |
Statistik
International
| Dänemark | 21 |
| Frankreich | 11 |
| Schweden | 7 |
| Vereinigtes Königreich | 6 |
| Schweiz | 5 |
Sektoral
| Health Technology | 29 |
| Consumer Services | 13 |
| Commercial Services | 6 |
| Finance | 4 |
| Producer Manufacturing | 2 |
Operativ
| Director/Board Member | 438 |
| Chairman | 182 |
| Corporate Officer/Principal | 155 |
| Independent Dir/Board Member | 95 |
| Chief Executive Officer | 69 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Eva Steiness
- Unternehmensverbindungen
